Table 2.
Preference in the choice of vaccines against COVID-19 and the proportion of vaccine acceptance compared to those who previously refused vaccination
| Vaccines | n (%) | Previously COVID-19 vaccine hesitancy before choosing a vaccine type (N = 671) n (%) |
|---|---|---|
| Sputnik V (Russia) | 202 (22.7) | 89 (13.3) |
| Sputnik V (Kazakhstan) | 100 (12.5) | 39 (5.8) |
| JNJ-78436735 (Johnson & Johnson, Netherlands, USA) | 68 (7.7) | 40 (6.0) |
| QazCovid-In (Kazakhstan) | 66 (7.4) | 27 (4.0) |
| AstraZeneca (Covishield, UK) | 66 (7.4) | 38 (5.7) |
| Moderna (Moderna, BARDA, NIAID, USA) | 61 (6.9) | 35 (5.2) |
| Comirnaty (Pfizer, BioNTech; Fosun Pharma) | 49 (5.5) | 24 (3.6) |
| CoronaVac (Sinovac, China) | 31 (3.5) | 19 (2.8) |
| BBIBP-CorV (China) | 20 (2.3) | 10 (1.5) |
| Convidicea (Ad5-nCoV), CanSino Biologics (China) | 14 (1.6) | 6 (0.9) |
| EpiVacCorona (Russia, Turkmenistan) | 10 (1.1) | 6 (0.9) |
| Covaxin (Bharat Biotech, ICMR, India) | 10 (1.1) | 7 (1.0) |
| Total | 697 | 207 (30.8)* |
*Since respondents had the option to choose several vaccines, this number summarizes the total number of respondents who indicated at least one type of vaccine.